Pharmacological Characterization of the Nociceptin/Orphanin FQ Receptor Antagonist SB-612111 [(–)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5 H-benzocyclohepten-5-ol]: In Vitro Studies
Barbara Spagnolo(University of Salento), Girolamo Calò(University of Padua), Martina Fantin, Carmela Fischetti, Michele Morari(University of Padua), Giulia Fanton, Christopher Hebbes, Giacomo Carrà, D. Regoli(University of Ferrara), Claudio Trapella(University of Ferrara), Anna Rizzi(University of Ferrara), John McDonald, Timothy Barnes(Johns Hopkins University)
Cited by 97
Related Papers
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease
|Nature Genetics|2011|2k
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
|Progress in Neurobiology|2015|472
Pharmacology of nociceptin and its receptor: a novel therapeutic target
|British Journal of Pharmacology|2000|432